NCT07175038: A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- State
- Under way
- Phase
- Phase 2
- People
- 40 planned
- Started
- 1 Oct 2025
- Primary completion
- Mar 2027
- Arms
- ROC-101 Oral Dose
- Results
- None posted
- 16 Sep 2025: Trial registered
- 1 Oct 2025: Trial started